-
2023-508259-38-00
5
2021-04-29
Adult patients with relapsed or primary refractory DLBCL
-
2023-505786-88-00
5
2021-04-25
Severe and inadequately controlled asthma
-
2024-512012-21-00
5
2021-04-08
Chronic Obstructive Pulmonary Disease
-
2023-509513-36-00
4
2021-03-24
Melanoma (Stage III and IV)
-
2024-511067-29-00
5
2021-01-25
IgA Nephropathy
-
2022-502031-20-00
10
2020-12-17
Non-squamous non-small cell lung cancer (NSCLC)
-
2024-510745-34-00
10
2020-11-11
Bullous Pemphigoid
-
2023-510107-22-00
5
2020-10-27
Hematopoietic stem cell transplant-associated thrombotic microangiopat
-
2024-517575-20-00
4
2020-08-24
different types of brain tumors
-
2024-513948-28-00
4
2020-05-08
unresectable stage III NSCLC (Non–small-cell lung cancer)
-
2023-507389-15-00
4
2020-02-26
Advanced Melanoma
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2022-502630-71-00
6
2019-11-20
Attention-deficit/hyperactivity disorder (ADHD)
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2023-509304-16-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2022-502938-30-00
5
2018-12-10
Moderate and Severe Atopic Dermatitis
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2023-506641-35-00
4
2018-07-09
Relapsed/Refractory Mantle Cell Lymphoma
-
2023-508859-39-00
10
2018-02-15
Autoimmune hepatitis
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)
-
2024-513167-68-00
5
2017-11-29
endometrial cancer